CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for BrightPath Biotherapeutics Co Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

BrightPath Biotherapeutics Co Ltd
7F, Kojimachi Central Bldg
2-2-4, Koji-machi
Phone: +81 444403939p:+81 444403939 CHIYODA-KU, TKY  102-0083  Japan Ticker: 45944594
Business Summary
BrightPath Biotherapeutics Co., Ltd. is a Japan-based company mainly engaged in the development of pharmaceutical products. The Company is a biopharmaceutical venture company focused on developing cancer immunotherapeutic. The Companies business model covers drug discovery research and early clinical development of cancer immunotherapy; conducting of early-phase clinical trials; and development, manufacturing, and launching of the drugs as commercial products in Japan and abroad. The Company also generates the revenues from license fees from the pharmaceutical companies.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/20233/31/2023Yes----

Industries
SIC Code Description
8731 Commercial physical and biological research
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
President, Chief Executive Officer, Representative Director KenichiNagai 49 3/1/2011 1/1/2009
Chief Financial Officer, Director YoichiTakeshita 53 6/1/2023 6/1/2023
Director of Drug Discovery Research, CSO, Director NorihiroNakamura 55 6/1/2018 6/1/2018
Director AkiraYamada 66 1/1/2004 5/1/2003
Independent Director HirotakaTakeuchi 77 6/1/2015 6/1/2015

General Information
Number of Employees: 32 (As of 3/31/2023)
Outstanding Shares: 70,741,299 (As of 3/27/2024)
Shareholders: 28,649
Stock Exchange: TYO
Fax Number: +81 942386564


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, April 18, 2024